| Literature DB >> 29233044 |
Guoping Zhang1, Xueyan Li2, Keyong Zhang2, Jingbo Zhao1, Changchun Qiu2,3.
Abstract
INTRODUCTION: The renin gene has been suggested as a good candidate in the study of genetic mechanism of essential hypertension. However, studies on the contribution of renin gene polymorphisms to essential hypertension, have not had consistent outcomes. The purpose of the present study is to explore the association of renin gene polymorphisms with essential hypertension in the Han population of northern China.Entities:
Keywords: Renin gene; essential hypertension; haplotype; intron; single-nucleotide polymorphism
Mesh:
Substances:
Year: 2017 PMID: 29233044 PMCID: PMC5843929 DOI: 10.1177/1470320317744917
Source DB: PubMed Journal: J Renin Angiotensin Aldosterone Syst ISSN: 1470-3203 Impact factor: 1.636
Demographic and clinical characteristics in essential hypertension (EH) and normotensive (NT) groups.
| Variables | EH (1533) | NH (1557) | ||
|---|---|---|---|---|
| Age (years) | 57.7±10.4 | 51.3±8.4 | 18.83 | <0.01 |
| AC (cm) | 84.5±10.3 | 78.4±8.5 | 17.86 | <0.01 |
| BMI (kg/m2) | 25.5±4.2 | 23.6±3.5 | 13.74 | <0.01 |
| SBP (mm Hg) | 149±19.7 | 119±12.6 | 50.93 | <0.01 |
| DBP (mm Hg) | 92.8±11 | 75.8±7.1 | 51.30 | <0.01 |
| TG (mmol/l) | 1.8±1.4 | 1.4±1.0 | 9.24 | <0.01 |
| HDL (mmol/l) | 1.5±0.6 | 1.6±0.7 | −2.23 | 0.03 |
| FBG (mmol/l) | 4.7±0.9 | 4.4±0.9 | 11.64 | <0.01 |
AC: abdominal circumference; BMI: body mass index; DBP: diastolic blood pressure; FBG: fasting blood glucose; HDL: high-density lipoprotein; SBP: systolic blood pressure; TG: triglyceride.
Figure 1.Sequencing figure of rs10900557. The arrow shows the variation sites.
Figure 2.3% Agarosel gel electrophoresis showing polymerase chain reaction (PCR) product of REN and rs2368564 polymorphism.
A: PCR product of Renin gene(REN), 250 bp; a: GG, 250 bp; b: GA, 250 bp+170 bp; c: AA, 170 bp+80 bp; B: 500 bp marker, 500 bp+400 bp+300 bp+200 bp+150 bp+100 bp+50 bp.
Distributional difference of genotypes and dominant models between cases and controls.
| SNP loci | EH | NT | FDR | OR (95% CI)* | ||
|---|---|---|---|---|---|---|
| rs11240687 | Genotype | |||||
| AA | 576 (37.6) | 582 (37.4) | 0.07 | 0.21 | 1.00 | |
| AG | 756 (49.3) | 729 (46.8) | 1.07 (0.89–1.28) | |||
| GG | 201 (13.1) | 246 (15.8) | 0.80 (0.63–1.03) | |||
| Allele | ||||||
| A | 1908 (62.23) | 1893 (60.79) | 1.00 | |||
| G | 1158 (37.77) | 1221 (39.21) | 0.24 | 0.29 | 0.94 (0.85–1.04) | |
| Dominant | ||||||
| AA | 576 (37.6) | 582 (37.4) | 1.00 | |||
| AG+GG | 957 (62.4) | 975 (62.6) | 0.98 | 0.98 | 1.00 (0.84–1.18) | |
| rs2177695 | Genotype | |||||
| TT | 30 (2.0) | 33 (2.1) | 0.24 | 0.29 | 1.00 | |
| TC | 333 (21.7) | 360 (23.1) | 0.86 (0.71–1.05) | |||
| CC | 1170 (76.3) | 1164 (74.8) | 0.75 (0.41–1.36) | |||
| Allele | ||||||
| C | 2673 (87.18) | 2688 (86.32) | 1.00 | |||
| T | 393 (12.82) | 426 (13.68) | 0.32 | 0.32 | 0.93 (0.80–1.08) | |
| Dominant | ||||||
| TT | 30 (2.0) | 33 (2.1) | 1.00 | |||
| TC+CC | 1503 (98.0) | 1524 (97.9) | 0.40 | 0.61 | 1.29 (0.71–2.34) | |
| rs10900557 | Genotype | |||||
| CC | 612 (39.9) | 588 (37.8) | 0.11 | 0.23 | 1.00 | |
| CT | 735 (48.0) | 738 (47.4) | 0.99 (0.83–1.18) | |||
| TT | 186 (12.1) | 231 (14.8) | 0.77 (0.60–1.00) | |||
| Allele | ||||||
| C | 1959 (63.89) | 1914 (61.46) | 1.00 | |||
| T | 1107 (36.11) | 1200 (38.54) | 0.05 | 0.14 | 0.90 (0.81–0.99) | |
| Dominant | ||||||
| CC | 612 (39.9) | 588 (37.8) | 1.00 | |||
| CT+TT | 921 (60.1) | 969 (62.2) | 0.41 | 0.61 | 0.93 (0.79–1.10) | |
| rs10900556 | Genotype | |||||
| GG | 426 (27.79) | 474 (30.4) | 0.37 | 0.37 | 1.00 | |
| GA | 747 (48.73) | 729 (46.4) | 1.09 (0.90–1.32) | |||
| AA | 360 (27.29) | 354 (22.7) | 1.18 (0.93–1.47) | |||
| Allele | ||||||
| G | 1599 (52.15) | 1677 (53.85) | 1.00 | |||
| A | 1467 (47.85) | 1437 (46.15) | 0.18 | 0.27 | 1.07 (0.97–1.18) | |
| Dominant | ||||||
| GG | 426 (27.8) | 474 (30.4) | 1.00 | |||
| GA+AA | 1107 (72.2) | 1083 (69.6) | 0.22 | 0.61 | 1.12 (0.93–1.34) | |
| rs11240686 | Genotype | |||||
| CC | 594 (38.8) | 591 (38.0) | 0.15 | 0.23 | 1.00 | |
| CT | 750 (48.9) | 732 (47.0) | 1.03 (0.86–1.23) | |||
| TT | 189 (12.3) | 234 (15.0) | 0.81 (0.63–1.04) | |||
| Allele | ||||||
| C | 1938 (63.21) | 1914 (61.46) | 1.00 | |||
| T | 1128 (36.79) | 1200 (38.54) | 0.16 | 0.27 | 0.93 (0.84–1.03) | |
| Dominant | ||||||
| CC | 594 (38.8) | 591 (38.0) | 1.00 | |||
| CT+TT | 939 (61.3) | 966 (62.0) | 0.76 | 0.82 | 0.98 (0.82–1.15) | |
| rs2368564 | Genotype | |||||
| GG | 984 (64.2) | 1203 (77.3) | <0.01 | 0.00 | 1.00 | |
| GA | 498 (32.5) | 336 (21.6) | 1.97 (1.63–2.38) | |||
| AA | 51 (3.3) | 18 (1.2) | 3.63 (1.96–6.71) | |||
| Allele | ||||||
| G | 2466 (80.43) | 2742 (88.05) | 1.00 | |||
| A | 600 (19.57) | 372 (11.95) | <0.01 | 0.01 | 1.79 (1.52–2.11) | |
| Dominant | ||||||
| GG | 984 (64.2) | 1203 (77.3) | 1.00 | |||
| GA+AA | 549 (35.9) | 354 (22.7) | <0.01 | 0.00 | 2.06 (1.71–2.47) | |
AC: abdominal circumference; BMI: body mass index; CI: confidence interval; FBG: fasting blood glucose; HDL: high-density lipoprotein; OR: odds ratio; TG: triglyceride.
Adjusted age, family history of EH, gender, AC, BMI, TG, HDL, and FBG.
The haplotype frequencies of six single-nucleotide polymorphisms (SNPs) and the distributions between cases and controls (the frequencies in both groups are more than 3%).
| Haplotype | Case (freq) | Control (freq) |
| FDR | OR (95% CI) |
|---|---|---|---|---|---|
| H1: A-C-C-A-C-A | 164 (0.05) | 154 (0.05) | 0.467 | 0.47 | 1.09 (0.87–1.36) |
| H2: A-C-C-A-C-G | 1263 (0.41) | 1238 (0.40) | 0.265 | 0.32 | 1.06 (0.96–1.18) |
| H3: A-T-C-G-C-A[ | 295 (0.10) | 158 (0.05) | <0.001 | 0.00 | 2.00 (1.63–2.44) |
| H4: A-T-C-G-C-G[ | 82 (0.03) | 236 (0.08) | <0.001 | 0.00 | 0.33 (0.26–0.43) |
| H5: G-C-T-G-T-A[ | 92 (0.03) | 34 (0.01) | <0.001 | 0.00 | 2.80 (1.87–4.14) |
| H6: G-C-T-G-T-G[ | 1006 (0.33) | 1122 (0.36) | 0.006 | 0.01 | 0.86 (0.77–0.96) |
CI: confidence interval; FDR: false discovery rate; OR: odds ratio.
Risk factor; bprotective factor.